
Syntekabio
Founded Year
2009Stage
IPO | IPOTotal Raised
$33.2MDate of IPO
12/17/2019About Syntekabio
Syntekabio is a genomic big data and AI-driven drug discovery & development company. The company uses its computational biology technologies for drug candidate discovery. It also specializes in co-developing drug response biomarkers of existing drug candidates, which allows improvement of the likelihood of successful clinical trials, biomarker-driven indication expansion, and enhanced understanding of the drug's mechanism of action.
Syntekabio's Products & Differentiators
DeepMatcher®
Physics- and deep learning-based virtual screening solution
Expert Collections containing Syntekabio
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Syntekabio is included in 2 Expert Collections, including Artificial Intelligence.
Artificial Intelligence
10,948 items
Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.
Digital Health
10,563 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Syntekabio Patents
Syntekabio has filed 7 patents.
The 3 most popular patent topics include:
- Genetics
- Learning methods
- Machine learning

Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
3/18/2021 | 1/4/2022 | Betacoronaviruses, Animal virology, Viral respiratory tract infections, Animal viral diseases, Zoonoses | Grant |
Application Date | 3/18/2021 |
---|---|
Grant Date | 1/4/2022 |
Title | |
Related Topics | Betacoronaviruses, Animal virology, Viral respiratory tract infections, Animal viral diseases, Zoonoses |
Status | Grant |
Latest Syntekabio News
Aug 31, 2023
Durham, NC | August 31, 2023 09:00 AM Eastern Daylight Time POLARISqb, the first company in the world to develop a drug discovery engine that utilizes the optimization power of quantum computing, announced that it has signed an MOU with Syntekabio (KOSDAQ: 226330), an Artificial Intelligence (AI) based drug development company. The partnership, which will combine the companies’ vanguard drug research platforms, will provide a collaborative drug development service as well as develop new molecular leads. Through this business agreement, the two companies will discover active compounds with their respective AI and Quantum Computing platforms. Using these technologies, they will search for candidates with high druggability potential and offer these candidates to customers seeking novel molecular leads. POLARISqb is a quantum computing-based drug development company in Durham, North Carolina. As a leader in applying quantum computing in the world of drug discovery, the company has shortened the timelines for finding novel drug-like leads by orders of magnitude. In addition, POLARISqb has recently developed Quantum-Aided Drug Design (QuADD), a platform for generating new drug candidates using quantum annealing from exceptionally large molecular libraries. Using the increased optimization power of today’s quantum computers, this process can be accomplished in days rather than months. In this partnership they will leverage this optimization potential of quantum annealing computers, allowing the company to search a chemical space of 1030 potential molecules, a space many times larger than other computational chemistry platforms. Based on its own cloud supercomputing infrastructure, Syntekabio prepares big genomic data and AI drug platform services for implementation throughout the entire life cycle of novel drug development processes. Their platform includes services from the discovery of active compounds to the development of pre-clinical stage drug candidates (called DDC Service: DeepMatcher® Drug Candidate Service), as well as genomic biomarker discovery and detection services. Syntekabio plans to diversify lead candidates by applying POLARISqb's QuADD platform in the lead generation stage of DDC service. In addition, the two companies plan to jointly market their offering to global markets with specific emphasis on the US, Europe, and Asia. Combining the advantages of POLARISqb's quantum-based system and Syntekabio's AI discovery platform enhances precision medicine. This partnership seeks to help develop treatments to address various conditions and diseases that affect millions around the globe. Shahar Keinan, co-founder and CEO of POLARISqb, said, “QuADD is a quantum computing-based platform that is relevant to the pharma global market, representing a commercialized quantum product in the field of new drug design.” She added, "We expect to be able to find lead candidates quickly and efficiently in this partnership by providing new drug development services using Syntekabio's cloud supercomputer infrastructure and genome-based AI platform." Jongsun Jung, CEO of Syntekabio, said, "We are delighted that Syntekabio's DeepMatcher® and POLARISqb's QuADD can cooperate to provide a drug candidate discovery service. It will be of great help in expanding global business opportunities as we work together.” For more information about POLARISqb and its offering, please visit:
Syntekabio Frequently Asked Questions (FAQ)
When was Syntekabio founded?
Syntekabio was founded in 2009.
Where is Syntekabio's headquarters?
Syntekabio's headquarters is located at Migun Techno World, Building 2-B, Room 512, Daejeon.
What is Syntekabio's latest funding round?
Syntekabio's latest funding round is IPO.
How much did Syntekabio raise?
Syntekabio raised a total of $33.2M.
Who are the investors of Syntekabio?
Investors of Syntekabio include Altos Ventures, Korea Asset Investment Securities Co., ASAM Asset Management, HB Advisors, Must Asset Management and 13 more.
Who are Syntekabio's competitors?
Competitors of Syntekabio include Acellera.
What products does Syntekabio offer?
Syntekabio's products include DeepMatcher® and 2 more.
Compare Syntekabio to Competitors
Cloud Pharmaceuticals, formerly TeraDiscoveries, is a leader in the computational design of new drugs and subsequent rapid, information-driven drug development. The company accelerates the drug discovery and design process in a way that delivers tangible results and true value for partners.
BioSolveIT visualizes drug discovery. Its software enables every chemist to advance their research. Perceptive visualization helps the users to understand computational results at a glance.

PharmEnable is a drug discovery company that uses a combination of medicinal chemistry and AI computational approaches to design small-molecule drugs. Its platform identifies novel active chemical starting points against biological targets, assisting the medical community to develop medicines such as novel antibacterial agents or potential cancer treatments. The company was founded in 2016 and is based in Cambridge, U.K.

Redesign Science is a computational chemistry company that engages in early-stage, small molecule drug discovery. The company efficiently simulates protein targets at the atomic level to reveal hidden, subtle drug opportunities that fall outside the capability, and scope of alternative computational models.
PharmCADD develops Pharmulator, a computer-aided drug discovery and development platform. The platform utilizes computational science methodologies, advanced machine learning technologies, and molecular dynamics. It was founded in 2019 and is based in Busan, South Korea.
Modulus Discovery operates as a preclinical-stage technology-driven drug discovery company. It leverages the synthesis of computational intelligence, biological inspiration, and global integration. It focuses on the rapid design and generation of small molecule clinical candidates for a range of high-value disease targets through the use of its computational drug discovery expertise and biology insights. The company was founded in 2016 and is based in Tokyo, Japan.